VERNON W ANTHONY
Known title: DirectorCIK: 0001369091
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
McCormick Analysts Lower Targets After Q3 Results. McCormick shares have come under pressure as several analysts, including UBS and TD Cowen, lowered their price targets following third-quarter results. While BNP Paribas maintained a positive outlook, the broader trend reflects reduced expectations for near-term growth. The company has also replaced its auditor with KPMG and reaffirmed its overall financial outlook despite the recent stock decline.
Transaction History
| NVCR | ▲ Buy | Grant | 11,610 | $0 | 6/3/2026 | View on chart |
| NVCR | ▼ Sell | Open Market | 2,945 | $46K | 6/2/2026 | View on chart |
| NVCR | ▲ Buy | Option Exercise | 21,500 | $245K | 4/28/2026 | View on chart |
| MKC | ▲ Buy | Option Exercise | 2,222 | — | 2/15/2026 | View on chart |
| NVCR | ▲ Buy | Grant | 11,215 | $0 | 6/4/2025 | View on chart |
| NVCR | ▼ Sell | Open Market | 999 | $17K | 6/3/2025 | View on chart |
| MKC | ▲ Buy | Option Exercise | 1,344 | $0 | 3/15/2025 | View on chart |
| NVCR | ▲ Buy | Grant | 4,053 | $0 | 6/5/2024 | View on chart |
| NVCR | ▼ Sell | Open Market | 964 | $23K | 6/4/2024 | View on chart |
| MKC | ▲ Buy | Option Exercise | 1,255 | — | 3/15/2024 | View on chart |
| NVCR | ▲ Buy | Grant | 3,853 | $0 | 6/7/2023 | View on chart |
| MKC | ▲ Buy | Option Exercise | 1,044 | $0 | 3/15/2023 | View on chart |
| MKC | ▲ Buy | Option Exercise | 1,139 | — | 3/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
NovoCure Gains Japan Approval for Optune Pax in Pancreatic Cancer
NovoCure received regulatory approval in Japan for Optune Pax to treat pancreatic cancer. This development is significant because it expands the potential market for the company's device. Analyst notes suggest this approval may shift the investment thesis by highlighting the firm's cash generation capabilities.
NovoCure Gains Japan Approval for Optune Pax in Pancreatic Cancer. NovoCure received regulatory approval in Japan for Optune Pax to treat pancreatic cancer. This development is significant because it expands the potential market for the company's device. Analyst notes suggest this approval may shift the investment thesis by highlighting the firm's cash generation capabilities.